AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01714986 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Affect School
Study NCT01714986 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body Awareness Therapy
Study NCT01810679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perceval S Aortic Heart Valve
Description: Perceval S Sutureless Aortic Heart Valve
Study NCT01711827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral
Study NCT01711827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: oral
Study NCT00801866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravitreal administration
Study NCT00801866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal Photocoagulation
Description: Panretinal Photocoagulation
Study NCT03112239 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Light-Emitting Diode Therapy (LEDT)
Description: Light-emitting diode, has effects similar to the photobiomodulation by low-level laser intensity.
Study NCT03112239 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light-Emitting Diode Therapy (LEDT)
Description: Light-emitting diode, has effects similar to the photobiomodulation by low-level laser intensity.
Study NCT01311466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Study NCT02975687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR T cells
Description: CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.
Study NCT02429531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23 (Sanofi Pasteur MSD)
Description: Intramuscular injection of Pneumovax 23 vaccine (0.5 ml).
Study NCT02429531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhim Vi (Sanofi Pasteur MSD)
Description: Intramuscular injection of Typhim Vi vaccine (0.5 ml).
Study NCT01758757 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy
Study NCT02883244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft-Picks Advanced
Description: Soft-picks Advanced will be used once a day to clean interdental sites at home.
Study NCT02883244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Floss
Description: Floss will be used once a day to clean interdental sites at home.
Study NCT02567929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol group
Description: Patient will be anesthetized by using propofol infusion during operation.
Study NCT02567929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane group
Description: Patient will be anesthetized by using sevoflurane inhalation during operation.
Study NCT02328066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBI used by trained endoscopists
Description: Examination of colon lesions, using NBI and NICE classification, by endoscopists who previously performed an easy learning program. The learning program consists on the reading of two reference articles and a tutorial explaining the NICE classification. This tutorial shows several lesions and describes the characteristic features in which the classifications focus on.
Study NCT01325012 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subgluteal Sciatic Nerve Block
Description: Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the subgluteal location 1-3 cm caudad to the inferior border of the gluteus maximus muscle. After catheter placement, outcome measures will be assessed.
Study NCT01325012 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Popliteal Sciatic Nerve Block
Description: Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After Catheter placement outcome measures will be assessed.
Study NCT01736046 — intervention group
Intervention type: RADIATION
Intervention: CT Enterography
Description: Diagnostic CT Enterography Scan (CTE)~Subjects will have their scheduled diagnostic CTE scan done according to St. Paul's Hospital radiology department standard procedures. Subjects will be randomly assigned to undergo a low dose CT Enterography scan either before or after the diagnostic scan. The radiologists who are blinded to the technique used will then interpret the scans to look for signs of Crohn's disease. The low dose scan will be compared to the standard scan in terms of it's ability to detect signs of Crohn's disease.
Study NCT01012492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
Study NCT01271621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation
Description: Endotracheal intubation
Study NCT01271621 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: Endotracheal intubation
Study NCT01155700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Study NCT01200745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin patch
Description: Over an four-week period, the treatment group (n=30) uses capsaicin patch (100 mcg/3cc) at the tender point of neck for 12 hours a day; the control group (n=30) receives Hydrogel patch instead of capsaicin patch.
Study NCT01200745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin patch
Description: Over an four-week period, the treatment group (n=30) uses capsaicin patch (100 mcg/3cc) at the tender point of neck for 12 hours a day; the control group (n=30) receives Hydrogel patch instead of capsaicin patch.
Study NCT01361516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anaesthesia and Lithotripsy
Description: The efficacy of stone fragmentation during lithotripsy procedure is compared under two types of anaesthesia
Study NCT02153762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Locoid Lipocream
Description: Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
Study NCT00440557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa once weekly
Description: Epoetin alfa will be administered as a SC injection at initial dose of 10000 IU (once weekly for 44 weeks).
Study NCT00440557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa once every two weeks
Description: Epoetin alfa will be administered as a SC injection at initial dose of 20000 IU (once every 2 weeks for 44 weeks).
Study NCT02153762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Locoid Lipocream
Description: Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
Study NCT00867542 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT02321384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
Study NCT02321384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6889678
Description: RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
Study NCT02321384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO6889678 or matching placebo.
Study NCT02321384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: RTV will be administered orally as a single dose on Day 1 in RTV-boosted SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in RTV-boosted MAD cohorts.
Study NCT01273337 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD-401
Description: 3 mL ALDHbr cells isolated from autologous bone marrow given as a one-time infusion via intracarotid infusion.
Study NCT01273337 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Sham bone marrow harvest and sham product infusion procedures.
Study NCT01584544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Study NCT02153762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylatopic Plus
Description: Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
Study NCT00171821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Study NCT02763111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-085
Study NCT02763111 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01584544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral pills, 1650mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Study NCT02153762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylatopic Plus
Description: Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
Study NCT04067830 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT04067830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive usual care
Study NCT04067830 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Surgery
Description: Undergo laparoscopic surgery
Study NCT04067830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Surgery
Description: Undergo laparoscopic surgery
Study NCT04067830 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04067830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04067830 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04067830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04067830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training Device
Description: Use power lung device to complete RMT
Study NCT04067830 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video-Assisted Thoracic Surgery
Description: Undergo video-assisted thoracic surgery
Study NCT04067830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video-Assisted Thoracic Surgery
Description: Undergo video-assisted thoracic surgery
Study NCT01539980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sericin scaffold
Description: Device: wound dressing containing silk sericin A scaffold from silk sericin-polyvinyl alcohol-glycerin blending are applied on one half of the skin graft donor site Device: fine mesh gauze impregnated with paraffin and 0.5%chlorhexidine acetate (Bactigras, Smith\&Nephew, London, UK) are applied on the other half of the skin graft donor site
Study NCT02847598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: Administered as specified in the treatment arm.
Study NCT02847598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study NCT00130286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosiglitazone
Description: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Study NCT00130286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Study NCT00130286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant human growth hormone + rosiglitazone
Description: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)
Study NCT00130286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone + rosiglitazone
Description: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)
Study NCT02534636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Study NCT02534636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2a recombinant
Study NCT02534636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Study NCT02534636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00003454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stage IV Breast Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT01361763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: 110 mg twice daily
Study NCT01361763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelets
Description: 100mg once a day
Study NCT01360645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712 + ADT
Description: Tablet, Oral, 2 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
Study NCT01360645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo + ADT
Description: Placebo + FDA Approved Antidepressant (ADT)
Study NCT01360645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + ADT
Description: Placebo + FDA Approved Antidepressant (ADT)
Study NCT01324557 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CSII and MDI
Description: The aims of this study are to assess the potential efficacy and safety of insulin pump(MiniMed Paradigm® REAL-Time Revel™ Insulin Pump) to improve glycemic control in conjunction with continuous glucose monitoring (CGMS) for diabetic CAPD Patients.
Study NCT01324557 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: CSII and MDI
Description: The aims of this study are to assess the potential efficacy and safety of insulin pump(MiniMed Paradigm® REAL-Time Revel™ Insulin Pump) to improve glycemic control in conjunction with continuous glucose monitoring (CGMS) for diabetic CAPD Patients.
Study NCT01390792 — intervention group
Intervention type: DRUG
Intervention: Zanamivir hydrate
Study NCT00713219 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT, cetuximab, docetaxel
Description: IMRT will be administered in once daily fractions (2 Gy/day, Monday through Friday) over approximately 7 weeks to a goal of approximately 70 Gy. The chemotherapy regimen will begin with a loading dose of intravenous cetuximab (400 mg/m2) one week prior to the initiation of radiation therapy, followed by weekly administration of intravenous docetaxel (15 mg/m2) and intravenous cetuximab (250 mg/m2) for approximately 7 weeks concurrently with radiation. Patients will be evaluated weekly prior to their chemotherapy. All patients will be evaluated on an intention-to-treat basis.
Study NCT01769755 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDA001
Description: Cohort 1 Dose Level 1: ¼ unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.~Cohort 2 Dose Level 2: ½ unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.~Cohort 3 Dose Level 3: 1 unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.
Study NCT01769755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Controlled Placebo
Description: Cohort 1 Dose Level 1: ¼ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.~Cohort 2 Dose Level 2: ½ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.~Cohort 3 Dose Level 3: 1 unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.
Study NCT03163654 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery 1
Description: Following local anaesthesia (Articaine hydrochloride 4% with 1:200,000 epinephrine injection) administration, sulcular incisions were made in the recession's areas of teeth without damaging interdental papilla. Mucoperiosteal (MP) dissections were made using the periostal elevator creating the deep pouch beyond the mucogingival junction so that the (MP) flap could be moved coronally without tension. Porcine-derived acellular dermal collagen matrix (PADM) was positioned at the level of a cemento-enamel junction (CEJ) and skin tight for teeth to avoid forming a blood clot. Separate single sutures per tooth with 5-0 resorbable suture were used to stabilise graft. The tunnel flap was positioned coronally above the CEJ to completely cover the graft and sutured with non-resorbable polypropylene suture.
Study NCT03163654 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery 2
Description: Following local anaesthesia (Articaine hydrochloride 4% with 1:200,000 epinephrine injection) administration, sulcular incisions were made in the recession's areas of teeth without damaging interdental papilla. Mucoperiosteal (MP) dissections were made using the periostal elevator creating the deep pouch beyond the mucogingival junction so that the (MP) flap could be moved coronally without tension. Connective tissue graft was positioned at the level of a cemento-enamel junction (CEJ) and skin tight for teeth to avoid forming a blood clot. Separate single sutures per tooth with 5-0 resorbable suture were used to stabilise graft. The tunnel flap was positioned coronally above the CEJ to completely cover the graft and sutured with non-resorbable polypropylene suture.
Study NCT03909958 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electroacupuncture+Routine rehabilitation training Group
Description: Electroacupuncture： Major acupoints: Jiaji points. With urinary and stool dysfunction:+Shenshu (BL23) ,Huiyang(BL35).~Localization:Jiaji points of the upper 1 and the lower 1 segment of the Spinal cord injury plane, a total of 4 points.~Operation: Insert Jiaji points By using Hwato-brand disposable acupuncture needles(0.30mm\*50mm), with 0.5 inch from the median line and a depth of 50 to 60mm with perpendicular insertion.Then, participants will receive electroacupuncture treatment by connecting Han's pain irritant instrument (HANS100A) for 30min with the stimulation frequency of 2 /100 Hz and intensity of 1-2mA. Once a day, 5 days a week and rest 2 days, a week is one course and the duration need 12 courses.~Routine rehabilitation training:~Same as Routine rehabilitation training Group.
Study NCT03909958 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Routine rehabilitation training Group
Description: Routine rehabilitation training:~Participants with good spinal stability will receive sitting training as early as possible, and will carry out standing training if participants had no adverse reactions (postural hypotension, etc.) after sitting training. Muscle strength training will be performed in recovery phase, and functional movement training will be selected according to participants' conditions. Functional movement training and transfer training will be performed for 20min each time and once a day;Standing and walking training, 2 times a day, 30min each time.
Study NCT03973983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transgluteal pudendal nerve injection (TG-PNI)
Description: Ultrasound-guided transgluteal pudendal nerve local anesthetic injections
Study NCT03973983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Finger-guided transvaginal pudendal nerve injection (TV-PNI)
Description: Finger-guided transvaginal pudendal nerve local anesthetic injections
Study NCT00324168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: moxifloxacin 0.5% every one hour for 48 hours while awake and then every 2 hours until re-epithelialization
Study NCT00324168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antibiotics
Description: moxifloxacin 0.5% every one hour for 48 hours while awake and then every 2 hours until re-epithelialization
Study NCT00324168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical corticosteroid
Description: prednisolone phosphate 1% with preservative four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
Study NCT00324168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl and preservative (same as in steroid) four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week